Serotype-selective, small-molecule inhibitors of the zinc endopeptidase of botulinum neurotoxin serotype A
摘要:
Botulinum neurotoxin serotype A (BoNTA) is one of the most toxic substances known. Currently, there is no antidote to BoNTA. Small molecules identified from high-throughput screening reportedly inhibit the endopeptidase-the zinc-bound, catalytic domain of BoNTA-at a drug concentration of 20 mu M. However, optimization of these inhibitors is hampered by challenges including the computational evaluation of the ability of a zinc ligand to compete for coordination with nearby residues in the active site of BoNTA. No improved inhibitor of the endopeptidase has been reported. This article reports the development of a serotype-selective, small-molecule inhibitor of BoNTA with a K-i of 12 mu M. This inhibitor was designed to coordinate the zinc ion embedded in the active site of the enzyme for affinity and to interact with a species-specific residue in the active site for selectivity. It is the most potent small-molecule inhibitor of BoNTA reported to date. The results suggest that multiple molecular dynamics simulations using the cationic dummy atom approach are useful to structure-based design of zinc protease inhibitors. (c) 2005 Elsevier Ltd. All rights reserved.
[EN] SMALL-MOLECULE BOTULINUM TOXIN INHIBITORS<br/>[FR] INHIBITEURS DE TOXINE BOTULINIQUE DE TYPE PETITES MOLÉCULES
申请人:MAYO FOUNDATION
公开号:WO2008051197A2
公开(公告)日:2008-05-02
[EN] Small-molecule inhibitors of Botulinum toxin, including BoNTA, BoNTD and BoNTE are provided, as well as methods of using the inhibitors. [FR] L'invention concerne des inhibiteurs de type petites molécules de toxine botulinique, notamment BoNTA, BoNTD et BoNTE, ainsi que des procédés d'utilisation des inhibiteurs.